Literature DB >> 12797493

Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids.

E S Mendes1, A Pereira, I Danta, R C Duncan, A Wanner.   

Abstract

The vasoconstrictive efficacies of glucocorticosteroids (GS) are usually compared by the McKenzie skin-blanching test and taken as an index of relative potency. The rationale for the present study was to transpose the McKenzie test to the airway and to compare the airway vascular effects of three inhaled GS: beclomethasone dipropionate (BDP), fluticasone propionate (FP) and budesonide (BUD), in healthy subjects and patients with mild stable asthma. A soluble, inert gas-uptake method was used to measure airway blood flow (Qaw). Baseline mean+/-SD Qaw normalised for anatomical dead space was 53.1+/-1.4 microL x min(-1) x mL(-1) in healthy subjects (n=10) and 67.8+/-3 microL x min(-1) x mL(-1) in asthmatics (n=10). All GS caused a transient decrease in Qaw. The magnitude of the vasoconstriction was greater in asthmatics. The relative vasoconstrictive effect of BDP, FP and BUD was 1, 1.9, and 2.7, respectively, in asthmatics and 1, 3.3 and 3.0, respectively, in healthy subjects, as assessed by the dose required to decrease Qaw by 20%, from the baseline, 30-min postdrug inhalation. Therefore, measuring airway blood flow may be a useful, site-specific parameter to assess the tissue bioavailability and vasoconstrictive efficacy of inhaled glucocorticosteroids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797493     DOI: 10.1183/09031936.03.00072402

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

1.  Efficacy of nebulised budesonide versus oral prednisolone in acute severe asthma.

Authors:  Cuddalore Subramanian Arulparithi; Thirunavukkarasu Arun Babu; C Ravichandran; Indumathy Santhanam; B Sathyamurthi; S Parivathini; J Hemachitra
Journal:  Indian J Pediatr       Date:  2014-06-07       Impact factor: 1.967

2.  Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.

Authors:  René Aalbers; Martin Boorsma; Hanneke J van der Woude; René E Jonkers
Journal:  Respir Res       Date:  2010-05-28

3.  Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol.

Authors:  D l Turner; N Ferrari; W R Ford; E J Kidd; B Nevin; L Paquet; P Renzi; K J Broadley
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  Genomic and non-genomic actions of glucocorticoids in asthma.

Authors:  Abdullah A Alangari
Journal:  Ann Thorac Med       Date:  2010-07       Impact factor: 2.219

5.  Correlation of exhaled breath temperature with bronchial blood flow in asthma.

Authors:  Paolo Paredi; Sergei A Kharitonov; Peter J Barnes
Journal:  Respir Res       Date:  2005-02-10

6.  Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control.

Authors:  Mohammad Emami; Azadeh Tayebi; Mojgan Gharipour; Somayeh Farzamnia; Akbar Kargari Temyarti
Journal:  Adv Biomed Res       Date:  2014-02-28

Review 7.  The use of inhaled corticosteroids in pediatric asthma: update.

Authors:  Elham Hossny; Nelson Rosario; Bee Wah Lee; Meenu Singh; Dalia El-Ghoneimy; Jian Yi Soh; Peter Le Souef
Journal:  World Allergy Organ J       Date:  2016-08-12       Impact factor: 4.084

Review 8.  New Insights in Glucocorticoid Receptor Signaling-More Than Just a Ligand-Binding Receptor.

Authors:  Karin Scheschowitsch; Jacqueline Alves Leite; Jamil Assreuy
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-06       Impact factor: 5.555

9.  Role of Inhaled Steroids in Vascular Airway Remodelling in Asthma and COPD.

Authors:  Alfredo Chetta; Dario Olivieri
Journal:  Int J Endocrinol       Date:  2012-10-11       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.